source
- Takeda’s zasocitinib proves ‘top-notch’ for difficult-to-treat psoriasis in phase 3 updateTakeda has unveiled more data from its phase 3 trials of zasocitinib, demonstrating that the once-daily pill was able to clear or almost clear scalp psoriasis in 75% of patients.Fierce Biotech · 13d ago↗ source
- Racing Takeda, InnoCare reports TYK2 inhibitor win in phase 2 vitiligo trialA phase 2 trial of InnoCare Pharma’s TYK2 inhibitor soficitinib in nonsegmental vitiligo has hit its primary endpoint, clearing the Chinese biotech to advance into the phase 3 part of the study.Fierce Biotech · 13d ago↗ source
- FDA Issues Emergency Use Authorization for Drug for Short-Term Prevention of New World Screwworm in HorsesThe FDA today issued an Emergency Use Authorization (EUA) for Ivermectin Liquid for Horses (ivermectin oral solution) for the short-term prevention of New World screwworm (NWS) infestations (myiasi…